Cold Chain and Refrigerated Storage

Refrigerated storage for injectable peptides means two to eight degrees Celsius, chosen to slow chemical degradation substantially while staying clear of ice formation. The underlying arithmetic is Arrhenius: reaction rates fall roughly exponentially as temperature drops, so deamidation, oxidation and hydrolysis that would take weeks at ambient temperature take months in a refrigerator. Distribution is judged not by a single reading but by mean kinetic temperature, a weighted average that gives disproportionate weight to warm periods because the kinetics are non-linear.

Freezing is the failure most people underestimate. In solution, ice formation concentrates the remaining solutes, shifts the pH of certain buffers, and creates a large ice-water interface at which molecules unfold and aggregate, so a frozen and thawed vial can be more damaged than one left warm for the same period. That is why labelling for refrigerated biologics forbids freezing outright, why shipping validation uses data loggers, and why contact with a frozen gel pack makes a vial suspect.

What cold chain governs is whether an excursion matters, and the honest answer depends on the stability data the sponsor generated. Many approved products carry a defined room-temperature allowance for in-use convenience. That allowance is cumulative and specific to one formulation, and it cannot be transferred to a different product by analogy.

The persistent misreading is treating cold as self-certifying. Refrigeration does not restore an already degraded product and does nothing to endotoxin or to contamination introduced through a closure, since relevant organisms grow at refrigerator temperature. The grey market inverts it more crudely, offering continuous cold storage as evidence of quality for material whose identity and sterility were never established.